Connect your AI

Inogen INGN Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

ResMedRMD

——

Other financials

Income statement

Revenue$85.1M+3.4%

Gross profit$44.9M+1.7%

Operating income-$9.3M-21.9%

Net income-$8.3M-34.8%

EPS (diluted)-$0.30-20.0%

Balance sheet

Cash & equivalents$93.1M-21.7%

Total debt$16.9M-11.9%

Total equity$182.9M-7.6%

Total assets$285.9M-7.3%

Cash flow

Operating cash flow-$6.7M+60.2%

CapEx$210.0K-28.1%

Free cash flow-$6.9M+59.6%

Valuation

Market cap$174.63M-9.7%

Enterprise value$98.45M-9.5%

P/S0.5×-0.1×

Profitability

Gross margin52.8%-2.6pp

Operating margin-9.1%-0.8pp

Net margin-7.1%-0.8pp

FCF margin0.4%—

Returns & leverage

Return on equity-13.1%-0.9pp

Debt / equity0.1×0.0×

Current ratio3.1×0.0×

Where this comes from

Reported directly by Inogen in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Inogen’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Inogen's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Inogen's payments for repurchase of common stock?: Inogen (INGN) reported payments for repurchase of common stock of $1.87M in Q1 2026.